FS KKR Capital Q4 Adjusted Net Investment Income, Total Investment Income Decrease-March 2024-www.financetom.com

FS KKR Capital Q4 Adjusted Net Investment Income, Total Investment Income Decrease

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

FS KKR Capital Q4 Adjusted Net Investment Income, Total Investment Income Decrease

Feb 26, 2025 2:32 PM

05:12 PM EST, 02/26/2025 (MT Newswires) -- FS KKR Capital ( FSK ) reported Wednesday Q4 adjusted net investment income of $0.66 per share, down from $0.75 a year earlier.

Analysts polled by FactSet expected $0.67.

Investment income for the quarter ended Dec. 31 was $407 million, down from $447 million a year earlier.

Analysts surveyed by FactSet expected $419.6 million.

Shares were down over 1% in after-hours activity.

Previous page： Rithm Capital Launches Preferred Stock Offering Next page： Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Rithm Capital Launches Preferred Stock Offering

Mar 11, 2026

09:52 AM EST, 01/13/2026 (MT Newswires) -- Rithm Capital ( RITM ) said Tuesday that it has launched an underwritten public offering of series F fixed-rate reset cumulative redeemable preferred stock based on market conditions. The company said it intends to list the preferred stock on the New York Stock Exchange under the symbol RITM PR F, and that terms...

Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

Mar 11, 2026

HAIFA, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, today announced that it has been granted two new U.S. patents that further expand and strengthen its global intellectual property portfolio supporting its proprietary Mitochondrial Augmentation Therapy (MAT) platform. The...

US FDA requests removal of suicide warnings from weight-loss drugs

Mar 11, 2026

Jan 13 (Reuters) - The U.S. Food ‌and Drug Administration on ‍Tuesday requested ⁠companies ⁠to ‌remove warnings related to ⁠the potential ‍risk of suicidal ideation and ‍behavior from the labeling of popular ‍weight-loss drugs of the GLP-1 class. ...

--Street Color: Meta Platforms, EssilorLuxottica in Potential Talks to Double Ray-Ban Glasses Output, Bloomberg Reports

Mar 11, 2026

09:54 AM EST, 01/13/2026 (MT Newswires) -- Price: 635.04, Change: -6.93, Percent Change: -1.08 ...